Examinando por Materia "Acetylcholine"

Mostrando 1 - 3 de 3
  • Publicación
    Acceso abierto
    Chemosensory disturbances-associated nanocholinergic dysfunction : The case of, not only, myasthenia gravis
    (2015-09-01) Leon Sarmiento, Fidias E.; Leon-Ariza, Juan S.; Prada, Diddier G.; Leon-Ariza, Daniel S.
  • Publicación
    Acceso abierto
    Sensory aspects in myasthenia gravis : A translational approach
    (2016-09-15) Leon-Sarmiento, Fidias E.; Leon-Ariza, Juan S.; Prada, Diddier G.; Leon-Ariza, Daniel S.; Rizzo Sierra, Carlos V.
    Myasthenia gravis is a paradigmatic muscle disorder characterized by abnormal fatigue and muscle weakness that worsens with activities and improves with rest. Clinical and research studies done on nicotinic acetylcholine receptors have advanced our knowledge of the muscle involvement in myasthenia. Current views still state that sensory deficits are not “features of myasthenia gravis”. This article discusses the gap that exists on sensory neural transmission in myasthenia that has remained after > 300 years of research in this neurological disorder. We outline the neurobiological characteristics of sensory and motor synapses, reinterpret the nanocholinergic commonalities that exist in both sensory and motor pathways, discuss the clinical findings on altered sensory pathways in myasthenia, and propose a novel way to score anomalies resulting from multineuronal inability associated sensory troubles due to eugenic nanocholinergic instability and autoimmunity. This medicine-based evidence could serve as a template to further identify novel targets for studying new medications that may offer a better therapeutic benefit in both sensory and motor dysfunction for patients. Importantly, this review may help to re-orient current practices in myasthenia.
  • Publicación
    Acceso abierto
    Smell status in functional movement disorders : New clues for diagnosis and underlying mechanisms
    (2019) Leon Sarmiento, Fidias E.; Bayona Prieto, Jaime; Leon Ariza, Juan S.; Leon Ariza, Daniel S.; Jacob, Alexandra E.; LaFaver, Kathrin; Doty, Richard L.
    Objective: Functional movement disorders (FMDs) mimic a range of movements, neuropsychiatric and neurodegenerative disorders known to have smell dysfunction, which has been neglected in terms of its application to FMD. We aim to determine the smell status in FMD patients tested by a non-invasive, reliable and validated olfactory test. Patients and methods: We quantitatively assessed in thirty-five FMD patients their smell status and compared it to that of healthy age- and sex-matched controls, and of patients with Parkinson’s disease (PD). All participants were administered the Brief Smell Identification Test (B-SIT), a standardized short version of the University of Pennsylvania Smell Identification Test (UPSIT). The Picture Identification Test (PIT), a visual test analogous in content and form to the UPSIT designed to control for non-olfactory cognitive confounds, was also administered. Results: The B-SIT scores of the FMD patients were higher than those from PD patients [respective means (standard deviations: SDs) = FMD, 9.54 (1.57); PD, 4.64 (1.05), p < 0.01)] but similar to the smell scores from healthy controls [9.97 (1.77), p=0.35]. Gender, age, time of disease onset, smoking status, and phenotypic expression did not influence the test scores. Fourteen FMD patients who mentioned having olfactory dysfunction before smell testing have their test results within normal range. PIT scores from patients and healthy controls were within normal range. Conclusions: These findings indicate that FMD patients have normal olfactory function. Olfactory testing may be helpful in identifying and differentiating FMD from other movement, neurodegenerative and neuropsychiatric diseases for which smell function is altered.